itinai content

  • AI News
  • AI Sales
  • Apple AI
  • Biohacking
  • Clinical Trials
  • Compare
  • Computer Vision
  • DeepSense
  • farma
  • Instruments
  • Management
  • Marketing
  • Marktechpost
  • Open AI
  • resume
  • КП
  • Migraine induced by vascular K(ATP) channel activation is independent of HCN channel activity: A randomised controlled trial with translational validation

    3 апреля, 2026

    ObjectiveTo investigate whether blockade of hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels modifies migraine induced by activation of vascular ATP-sensitive potassium (K(ATP)) channels.MethodsWe conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with migraine without aura. On two separate days, participants received intravenous levcromakalim followed immediately by either oral ivabradine or placebo in a balanced… →

    Clinical Trials
  • Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

    3 апреля, 2026

    INTRODUCTION: Early identification of patients with high cardiorenal risk and timely targeted interventions are critical in managing type 2 diabetes (T2D). Although we previously developed a multivariable risk score to predict diabetic kidney disease (DKD), its ability to stratify cardiorenal risk in T2D patients with established high cardiovascular risk remains unknown. →

    Clinical Trials
  • Sales outreach tools that integrate with your CRM: Our favorite picks for 2026

    3 апреля, 2026

    Most salespeople spend only around Sales outreach tools address these issues directly, but only when they work closely with the CRM. When outreach pulls from live account and deal data — and logs activity back automatically — follow-ups stay relevant, ownership stays clear, and teams don’t have to clean up after every campaign. Table of… →

    AI Sales
    AI, Analytics, B2BMarketing, B2BSales, BrandStrategy, ContentMarketing, ConversionOptimization, CustomerExperience, DataDriven, DigitalMarketing, Ecommerce, GrowthHacking, InboundMarketing, LeadGeneration, MarketingAutomation, MarketingTips, Salesforce, SEO, SocialSelling, TechnologyTrends
  • Best scheduling apps that sync with your CRM in 2026

    3 апреля, 2026

    Sales professionals who use The best scheduling app with CRM integration goes beyond creating calendar entries, transforming a sales team’s entire scheduling workflow into an automated lead conversion machine. This guide breaks down what separates truly integrated scheduling solutions from basic booking tools, how to evaluate options, and which top scheduling apps deliver seamless CRM… →

    AI Sales
    AI, Analytics, B2BMarketing, B2BSales, BrandStrategy, ContentMarketing, ConversionOptimization, CustomerExperience, DataDriven, DigitalMarketing, Ecommerce, GrowthHacking, InboundMarketing, LeadGeneration, MarketingAutomation, MarketingTips, Salesforce, SEO, SocialSelling, TechnologyTrends
  • Sales workflow automation: How to build sequences that convert prospects faster

    3 апреля, 2026

    Customer expectations are rising, and today’s buyers are demanding instant responses, personalized conversations, and frictionless experiences. Companies meeting these criteria are seeing Yet most reps are caught in a whirlwind of repetitive, manual tasks like data entry, email follow-ups, and internal coordination across disconnected systems, rather than giving buyers the fast, relevant responses they expect.… →

    AI Sales
    AI, Analytics, B2BMarketing, B2BSales, BrandStrategy, ContentMarketing, ConversionOptimization, CustomerExperience, DataDriven, DigitalMarketing, Ecommerce, GrowthHacking, InboundMarketing, LeadGeneration, MarketingAutomation, MarketingTips, Salesforce, SEO, SocialSelling, TechnologyTrends
  • Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial

    3 апреля, 2026

    CONCLUSIONS: The results of the FIRST-NIS support Rd as an effective and safe frontline treatment option for patients with TIE NDMM, irrespective of age, with similar clinical outcomes in the real world compared to the pivotal trial. →

    Clinical Trials
  • Long-term brain pressure monitoring via a discrete microimplant; a first-in-human safety and initial efficacy trial in adults and children with hydrocephalus

    3 апреля, 2026

    Emerging neurotechnologies such as brain-computer interfaces and implantable sensors offer considerable promise in the treatment of a broad range of neurological conditions. The key challenges are reducing the implant size, powering it, and confirming long-term accuracy and safety. Here we report the development of a novel type of implantable medical device that measures intracranial pressure… →

    Clinical Trials
  • Advancing neonatal jaundice screening with mHealth: a mixed-methods randomised controlled feasibility study in a resource-limited setting in Mexico

    3 апреля, 2026

    CONCLUSIONS: Implementing Picterus Jaundice Pro yielded encouraging improvements in screening practices, underscoring its potential to advance neonatal care. Addressing systemic barriers and raising awareness among parents and healthcare workers is crucial for maximizing impact. →

    Clinical Trials
  • Double-blind randomized control trial investigating immediate changes in pain processing measures in response to dry needling to the lumbar multifidus in an asymptomatic population

    3 апреля, 2026

    CONCLUSION: A significant main effect was observed in response to DN and sham DN local to the intervention site. This finding suggests peripherally mediated shared mechanisms between DN and sham DN. Baseline pain modulatory efficiency and post-intervention expectations may be indicators of individuals who will experience a greater analgesic response to needling interventions. →

    Clinical Trials
  • [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study

    3 апреля, 2026

    BACKGROUND: [^(177)Lu]Lu-prostate-specific membrane antigen (PSMA)-617 (^(177)Lu-PSMA-617) is a novel treatment for metastatic castration-resistant prostate cancer. Here, we aimed to evaluate ^(177)Lu-PSMA-617 in patients with PSMA-expressing oligometastatic hormone-sensitive prostate cancer (HSPC). →

    Clinical Trials
1 2 3 … 933
Следующая страница